bluuebunny/crossref_metadata_2025_split huggingface dataset:
Histological, immunohistochemical, and chromosomal studies on non‐adrenal neuroblastomas without increased excretion of catecholamines and their metabolites in urine
Authors: Sakatoku H. , Komada Y. , Hamazaki Y. , Kamiya H. , Sakurai M. 
Published: February 2007

AbstractWe reviewed our records for the last 10 years and found three of the 36 patients with neuroblastoma did not excrete significantly increased quantities of catecholamine metabolites in urine. All of these tumors were histologically characterized by small round cells and possessed a few dense core granules on the electron microscopic examination. All of them were reacted with anti‐neuron‐specific enolase (NSE) antibodies, OKB2, Pl153/3 monoclonal antibodies (Mo‐Abs). The HNK‐1, BA‐1, and SJ‐9A4 MoAbs reacted with two out of three. One of them demonstrated a reciprocal translocation involving the short arm deletion of chromosome 1. This multidisciplinary study has been helpful in making more accurate diagnoses for neuroblastoma without classical clinical characters.
Breast nodules as the initial site of relapse in childhood leukemia
Authors: Weinblatt Mark E. , Kochen Joseph 
Published: February 2007

AbstractTwo children with acute monoblastic leukemia in remission developed breast nodules that were the initial sites of disease relapse. Shortly after the appearance of disease in this site, the children developed marrow recurrence and, despite additional treatment, rapidly deteriorated and died from pancytopenia‐related complications. The importance of careful breast examination is stressed as part of the surveillance physical examination for children with monoblastic leukemia.
Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German neuroblastoma trial
Authors: Klingebiel Thomas , Berthold Frank , Treuner Jörn , Schwabe Dirk , Fischer Manfred , Feine Ulrich , Maul Frank D. , Waters Werner , Wehinger Helmut , Niethammer Dietrich 
Published: February 2007

AbstractFrom 1984 to 1989, 47 children with relapsed, refractory, and/or metastasized neuroblastoma were treated with 131l‐metaiodobenzylguanidine (mlBG) in several different treatment combinations. At initial diagnosis, 36 children had Evans stage IV and 11 stage III disease. In 16 of the 47 children, tumor recurred after complete remission prior to mlBG treatment, 26 of 47 progressed from residual or nonresponding tumor, and in 5 of 47 tumor progression during chemotherapy was observed. Altogether the children were treated with a total of 112 courses (range 1–6) with a mean dosage of 8.9 ± 6.7 mCi/kg body weight/treatment course. Total dose was 283.2 ± 203.7 mCi for stage III and 388.9 ± 218.6 mCi for stage IV. Nine of 47 children reached a complete or a very good partial remission (CR and VGPR) from mlBG treatment alone, 13 of 47 achieved partial remission (PR). In an early analysis, 10 patients treated with mlBG in the neuroblastoma trial NB 85 of the German Society of Pediatric Oncology showed no significant difference in survival time compared with 30 conventionally treated children. However, the recent therapy series has been done with higher doses of mlBG, and during improved therapeutic scanning many more bone lesions could be detected than during earlier diagnostic scanning. We conclude that mlBG treatment has not yet fulfilled the expectations for it but still seems for certain indications to be a promising tool to treat neuroblastoma in the future. Moreover, the frontier of neuroblastoma detection is still advancing.
Longitudinal growth in children with non‐Hodgkin's lymphoma and children with acute lymphoblastic leukemia: Comparison between unirradiated and irradiated patients
Authors: Márky Ildikó , Samuelsson Bengt‐Olof , Mellander Lotta , Karlberg Johan 
Published: February 2007

AbstractLongitudinal growth was studied in children treated for non‐Hodgkin's lymphoma (NHL). The aim of the study was to compare these children's growth velocity with findings in a previous study we performed on age‐matched children with acute lymphoblastic leukemia (ALL) who received cranial irradiation. Nine children with NHL with an onset time of treatment between 4 and 9 years of age (mean 6.5 years) were studied with annual body measurements taken from the time of the diagnosis and thereafter annually during the following 4 years. None of the children received cranial irradiation. During the first treatment year a significantly low mean height velocity was observed (−1.4 standard deviation score [SDS]) for the NHL group. The consecutive two 1 year periods showed a normalization of the mean height velocity. For the group of children with ALL, there was a more prominent negative effect on height during the first 2 years of treatment than for the NHL group in the present study. After the cessation of therapy, the children with NHL showed a reduced catch‐up growth compared with the children with ALL. The explanation offered is that cranial irradiation has a heavier impact on growth than chemotherapy during the first 2 years of treatment, but an intense chemotherapy during the maintenance period could have a considerable impact in blunting growth.
Bulbar and pseudobulbar palsy complicating therapy with high‐dose cytosine arabinoside in children with leukemia
Authors: Shaw Peter J. , Procopis Peter G. , Menser Margaret A. , Bergin Mary , Antony Jayne , Stevens Michael M. 
Published: February 2007

AbstractThree of 38 children given high‐dose cytosine arabinoside therapy developed a previously undescribed complication. Neurological problems are a frequent occurrence in patients given this therapy, particularly cerebellar ataxia, but the development of bulbar and pseudobulbar palsy has not been reported. In two of these cases, it was sufficiently marked for the course of treatment to be curtailed and occurred at a relatively low cumulative dose of the drug. Neurotoxicity can occur at any time using high‐dose cytosine therapy.
Autologous bone marrow transplantation with 4‐hydroperoxycyclophosphamide‐purged marrow for acute lymphoblastic leukemia
Authors: Gonzales‐Chambers Rowena , Przepiorka Donna , Shadduck Richard K. , Borochovitz Dennis , Bloom Elana J. , Colvin O. Michael , Mangan Kenneth F. , Rosenfeld Craig S. 
Published: February 2007

AbstractTen patients age 13–52 years with acute lymphoblastic leukemia (ALL) in first complete remission (CR) (1), second CR (6), or relapse (3) were treated with cyclophosphamide 50 mg/kg daily × 4 and total body irradiation 3 Gy daily × 4 followed by infusion of autologous marrow purged with 4‐hydroperoxycyclophosphamide (4‐HC) at 100–120 μg/mL. The patients transplanted in relapse also received 2 mg vincristine and corticosteroids. All marrows were harvested while patients were in CR. The nucleated marrow cell dose was 3.5 ± 0.7 × 108/kg, and the CFU‐GM content of the transplant was 0.4 ± 0.5 × 103/kg after purging with 4‐HC. Median time from transplantation is 48 months. The neutrophil count (ANC) exceeded 1.0 × 109/L at a median of 26 days and platelets exceeded 50 × 109/L at 34 days. All patients were in remission after transplantation (ABMT). Five patients relapsed 2–9 months after ABMT (actuarial rate 60%). Three patients are alive and in CR at 17+, 43 +, and 54+ months after ABMT. Purging marrow with 4‐HC did not adversely affect engraftment, but it is not clear if the high relapse rate was due to incomplete ex vivo purging or inadequacy of the conditioning regimen.
Malignant lymphomas in children in the Netherlands in the period 1973‐1985: Incidence in relation to leukemia: A report from the dutch childhood leukemia study group
Authors: Coebergh Jan Willem W. , van der Does‐van den Berg Anna , Kamps Willem A. , Rammeloo Johan A. , Valkenburg Hans A. , van Wering Elisabeth R. 
Published: February 2007

AbstractA retrospective study was done of the incidence of non‐Hodgkin's lymphoma (NHL) in children in the Netherlands in the period 1973‐85 in relation to that of acute lymphoblastic leukemia (ALL). Complete ascertainment of cases was most likely achieved through the network of cooperating pediatricians of the Dutch Childhood Leukemia Study Group (DCLSG). The incidence of NHL remained constant at 0.75 per 105 children per year; the boy/girl ratio was 2.5. In ±25% of cases the disease was localized at diagnosis. Of children with NHL who were not listed in the DCLSG leukemia register, 19% had ±25% lymphoblasts in the bone marrow at diagnosis, representing an overlap with ALL of ±5%. In 1% of the children with NHL an immuno‐deficiency disorder preceded the diagnosis. The incidence of Hodgkin's disease (HD) was 0.3 per 105 children per year, with some fluctuation over time, the peak being 0.7 in 1983. The boy/girl ratio was 2.7. Age‐specific incidence rates, clinical features of NHL and HD, as well as the ALL to NHL ratio corresponded with those in other European countries and for white children in the USA.
Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma
Authors: Griebel Maye , Friedman Henry S. , Halperin Edward C. , Wiener M. David , Marks Lawrence , Oakes W. Jerry , Hoffman John M. , DeLong G. Robert , Schold S. Clifford , Hockenberger Beverly , Freeman Carolyn R. , Kun Larry 
Published: February 2007

AbstractTwo patients with brain stem gliomas were treated with hyperfractionated radiation therapy (HFR) (7,020 and 7,560 cGy, respectively). Despite initial clinical improvement during irradiation, both patients demonstrated clinical deterioration approximately 3 weeks after completion of radiotherapy. Cranial magnetic resonance imaging (MRI) revealed a progressive increase in distribution of abnormal brain stem signal consistent with either tumor or edema. 18FDG positron emission tomography (PET) was obtained in one patient and demonstrated a hypermetabolic lesion at diagnosis and a hypometabolic lesion at the time of clinical deterioration postirradiation. Management with a tapering dose of dexametha‐sone alone resulted in marked clinical (both patients) and radiogaphic (one patient) improvement, allowing reduction or discontinuation of this medication. These results suggest that patients with brain stem tumors demonstrating clinical and radiographic evidence of progressive tumor shortly after completion of HFR should be initially managed conservatively with dexamethasone, since these findings may be manifestations of reversible radiation‐related neurotoxicity.
Pancreatoblastoma: Response to chemotherapy
Authors: Vannier Jean‐Pierre , Flamant Françoise , Hemet Jacques , Caillaud Jean Michel , Gruner Max , Bachy Bruno , Lefur René , Lemerle Jean , Tron Philippe 
Published: February 2007

AbstractTwo cases of pancreatoblastoma in children are reported here. Only biopsies were made at laparotomy as surgical resection by duodeno‐pancreatectomy was not possible. In both children a dramatic response was observed with chemotherapy: doxorubicin plus cisplatin for one, cyclophosphamide, actinomycin D, bleomycin, vinblastin sulfate, and cisplatin for the other. After completion of the chemotherapy the first patient had a local resection; then he had radiotherapy. He is alive in first remission 40 months after the end of the treatment. In the second patient, regional recurrence occurred 8 months after chemotherapy was ended. A transient second remission was obtained with ifosfamide plus etoposide alternating with epirubicin plus vincristine. The patient died 36 months after the diagnosis. Therefore, these two cases suggest that chemo therapy may be proposed before any attempt at surgical excision. Nevertheless, early consolidation by radical resection or irradiation must be considered.
Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: A siop pilot study
Authors: Ninane Jacques , Perilongo Giorgio , Stalens Jean‐Philippe , Guglielmi Maurizio , Otte Jean‐Bernard , Mancini Antonia 
Published: February 2007

AbstractSixteen children, aged 16 days to 13 years with hepatoblastoma (HB) (13 patients) or hepatocellular carcinoma (HCC) (3 patients), were given a total of 89 courses of cisplatin and doxorubicin (PLADO) as IV continuous infusion. All tumors were confined to the liver except for 1 hepatoblastoma patient with pulmonary metastases at presentation. Tumor response to PLADO was evaluable in 10 children (8 HB, 2 HCC) treated with preoperative chemotherapy and in another 2 HB patients treated when they developed pulmonary metastases after initial treatment with surgery alone. There were 2 complete responses (2 HB with pulmonary recurrences), 7 very good partial responses (6 HB and 1 HCC), 2 partial responses (1 HB, 1 HCC), and 1 stable disease (HB). The last patient underwent orthotopic liver transplantation whereas all the other patients had their tumor completely excised at delayed surgery. Documented toxicity was BM depression (16 patients), infection (11), vomiting (11), mucositis (3), hearing loss (1), and cardiotoxicity (1). These data indicate that PLADO in continuous infusion is effective in the treatment of malignant epithelial liver tumors with acceptable toxicity.
Germ cell tumors in children: Gonadal and extragonadal
Authors: Wollner Norma , Ghavimi Fereshteh , Wachtel Antonio , Luks Enrique , Exelby Philip , Woodruff James 
Published: February 2007

AbstractSixty‐three pediatric patients with germ cell tumors are presented with details of symptoms, histological findings, staging, serological markers, treatment, and response to therapy. The primary sites were: ovarian 32, testicular 17, presacral 7, mediastinal 3, intraabdominal 2, vaginal 1, and right inguinal canal 1. These patients were treated with T2 (sequential use of dactinomycin, doxorubicin, vincristine, and cyclophosphamide, with or without radiation), T6 (combination chemotherapy with cyclo‐phosphamide, bleomycin, dactinomycin, doxorubicin, methotrexate, vincristine), or VAB treatment protocols (velban, dactinomycin, bleomycin, cisplatin). The cure rate for stage I ovarian and testicular germ cell tumors was 100%; for stage III, all primary sites, 82% and for stage IV, all primary sites, 75%. Histology was prognostic in ovarian tumors of the immature malignant teratoma type; the neural type immature teratoma, grades II and III, had the worst prognosis. Initial debulking surgery in combination with chemotherapy and radiation plays an important role in germ cell tumors. Stages II, III, and IV germ cell tumors require aggressive treatment with surgery, radiation, and chemotherapy. For stage I patients, with primary ovarian malignant tumor, cure with surgery alone can be achieved in 50% of the cases and in testicular tumors in about 70% of the patients. For those with stage I and elevated serological markers, it is feasible to follow these markers and give no treatment until there is evidence of persistent elevation or a rise in titers after an initial fall. In those without elevated serological markers, one should take into consideration the size of the tumor and the histological type before taking the “wait and see” approach. These stage I tumors are highly curable when they first present but, if allowed to recur, chemotherapy may not offer the patient such a favorable response and cure rate.
Late orthopedic effects in children with Wilms' tumor treated with abdominal irradiation
Authors: Rate William R. , Butler Mark S. , Robertson William W. , D'Angio Giulio J. 
Published: February 2007

AbstractBetween 1970 and 1984, 31 children with biopsy‐proven Wilms' tumor received nephrectomy, chemotherapy, and abdominal irradiation and were followed beyond skeletal maturity. Three patients (10%) developed late orthopedic abnormalities requiring intervention. Ten children received orthovoltage irradiation, and all cases requiring orthopedic intervention or developing a scoliotic curve of >20d̀ were confined to this group, for a complication frequency of 50%. Those children who developed a significant late orthopedic abnormality (SLOA) as defined were treated to a higher median dose (2,890 cGy) and a larger field size (150 cm2) than those who did not (2,580 cGy and 120 cm2). Age at irradiation, sex, and initial stage of disease did not appear to influence the risk of developing an SLOA. No child who received megavoltage irradiation developed an SLOA despite treatment up to 4,000 cGy or to field sizes of 400 cm2. We conclude that modern radiotherapy techniques rarely lead to significant late orthopedic abnormalities previously associated with abdominal irradiation in children with Wilms' tumor.
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A cancer and leukemia group b study
Authors: Dawson Nancy A. , Costanza Mary E. , Korzun Ann H. , Clamon Gerald H. , Pollak Michael , Vogelzang Nicholas J. , Carey Robert W. , Norton Larry 
Published: February 2007

AbstractTwenty‐two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX). Patients received TMTX 8 mg/m2/day if previously treated or 12 mg/m2/day if previously untreated, both given by intravenous bolus days 1–5, every 21 days. None of the patients previously treated for metastatic disease responded to TMTX. There was one partial responder among the 22 patients with previously untreated metastatic disease. The primary toxicity was hematologic and occurred more frequently in patients with a pleural effusion, low serum protein or albumin, or poor performance status. There were three toxic deaths. The study for previously untreated patients required cyclo‐phosphamide, doxorubicin, and 5‐fluorouracil (CAF) after 4 cycles of TMTX. This study design for previously untreated patients allows the Cancer and Leukemia Group B (CALGB) to prospectively evaluate the activity of new agents in “chemotherapy‐sensitive” metastatic breast cancer.
Percutaneous lumbar intrathecal catheter for the administration of chemotherapy
Authors: Tobias Joseph D. , Oakes Linda , Foreman Nicholas K. , Mahmoud Hazem 
Published: February 2007

AbstractWe present a patient with Burkitt's lymphoma in whom the initial diagnostic lumbar puncture was difficult due to a recent lumbar laminectomy and residual spinal cord tumor. According to our current protocol, he was to receive intrathecal chemotherapy for three consecutive days. To avoid the need for repeated attempts at lumbar puncture and to ensure the proper instillation of therapy, a percutaneous IT catheter was placed for 48 hours and the three doses of IT chemotherapy were administered through this catheter. Due to the importance of IT chemotherapy, options must be available to deliver these medications when technical or anatomic abnormalities exist. One such option is the short term placement of a percutaneous IT catheter.
Osteoblastic metastases from astrocytomas: A report of two cases
Authors: Longee Darryl C. , Friedman Henry S. , Phillips Peter C. , Burger Peter C. , Oakes W. Jerry , Heffez Dan , Wharam Moody , Strauss Lewis , Fuller Gregory N. , Schold S. Clifford 
Published: February 2007

AbstractThe spread of primary central nervous system (CNS) neoplasms beyond the confines of the neuraxis is a relatively uncommon observation. Extraneural metastases involving bone are quite rare, and have been observed almost exclusively in cases of medulloblastoma, high‐grade (III‐IV) astrocytoma, and glioblastoma multiforme. To date there has been only one case reported of bone metastasis from a “well‐differentiated” astrocytoma. We now report two cases of astrocytoma in children with diffuse osteoblastic metastases and a fulminant clinical course. These cases demonstrate that due to the potential morphologic heterogeneity of these neoplasms, an initial biopsy diagnosis of low‐grade astrocytoma does not always imply a benign clinical course.
Malignant peritoneal mesothelioma: Long‐term spontaneous clinical remission
Authors: Schwartz Eliezer , Maayan Chaim , Mouallem Meir , Engelberg Santiago , Friedman Eitan 
Published: February 2007

AbstractProlonged spontaneous clinical remission in a patient with malignant peritoneal mesothelioma is described. The case is also unique because of the presence of highspiking fevers as a symptom of tumor recurrence and the finding of an elevated titer of rheumatoid factor in the ascitic fluid. The caution needed in interpreting results of therapeutic interventions in this tumor is emphasized.
Treatment of stage IV‐S neuroblastoma: A study of 34 cases treated between 1982 and 1987
Authors: Suarez Alcira , Hartmann Olivier , Vassal Gilles , Giron Alain , Habrand Jean Louis , Valteau Dominique , Brugieres Laurence , Kalifa Chantal , Lemerle Jean 
Published: February 2007

AbstractBetween January 1982 and December 1987, of 283 children with neuroblastoma treated in the Pediatric Department of Institut Gustave Roussy, 34 were stage IV‐S. Two groups were distinguished according to the initial clinical presentation: 16/34 patients had life‐threatening symptoms and needed immediate treatment, and 18/34 had no life‐threatening symptoms. Hepatic irradiation was used in 12/16 patients of the first group with respiratory distress. Chemotherapy was used in three patients. Of these 16 patients, three patients died of progressive disease (one patient died of a reason not related to the tumor). Twelve are alive in first complete remission and one in second complete remission. Of the 18, patients of the second group, eight had spontaneous complete remission, and one of them relapsed thereafter and died despite treatment. Ten patients needed treatment, radiotherapy, and/or chemotherapy depending on the site of disease progression. Two of them died of the disease. The overall disease‐free survival for these 34 patients is 75% at 90 months postdiagnosis. Using this therapeutic strategy, it was possible to avoid any treatment of metastases in 25% of the patients.
Lack of bcr rearrangement in juvenile chronic myeloid leukemia
Authors: Toren Amos , Mandel Mathilda , Amariglio Ninette , Hakim Ytzhak , Brok‐Simoni Frida , Rechavi Gideon , Neumann Yoram , Ramot Bracha 
Published: February 2007

AbstractJuvenile chronic myeloid leukemia (JCML) is an unusual subtype of children's leukemia, characterized by unique clinical presentation. Recent studies revealed several biological features, distinguishing from those observed in adult type chronic myeloid leukemia (ACML). The majority of ACML cases are characterized by the presence of an hybrid bcr‐abl rearranged gene. In an effort to elucidate the molecular basis of this unusual leukemia we looked for bcr rearrangement in six JCML cases. No bcr rearrangement was identified in any of the analyzed samples. Together with previous studies from JCML cases, JCML has a different mechanism of leukomogenesis from ACML.
Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens
Authors: Caron Hubert N. , Abeling Nico , van Gennip Albert , de Kraker Jan , Voucte P. A. 
Published: February 2007

AbstractWe monitored renal tubular function in 18 neuroblastoma patients treated with chemotherapeutic regimens containing Ifosfamide and platinates. The total IFO dose ranged from 30 to 48 g/m2. After each IFO course and at regular intervals during follow‐up 24 hour urinary excretion of aminoacids, qualitative excretion of protein and glucose, tubular reabsorption of phosphate, serum pH, and liver enzyme (SGOT and SGPT) were measured. The ratio of α‐amino‐Nitrogen/total‐Nitrogen (normal <2.5%) and the urinary excretion pattern were used to quantify the aminoaciduria In 12 out of 15 evaluable patients some degree of tubular toxicity occurred during treatment, slowly progressing to a Debré‐de Toni‐Fanconi syndrome (DTFS) in 7 patients. The DTFS was fully developed in most cases 3–9 months after the end of treatment and was reversible in 3 cases. Hyperaminoaciduria (HAA) occurred in all patients during treatment, preceding other signs of tubular toxicity. The maximum ratio measured before development of a DTFS was significantly higher in the patients with severe toxicity (P < .01). HAA characterized by a ratio >10% predicts the development of a DTFS with a sensitivity of 71.4% and a specificity of 87.4%.